دورية أكاديمية
أعرض في EDS

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.
المؤلفون: Wang JL; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China., Chen CS; Nanjing Medical University, Nanjing, 211166, China., Jia ZR; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China., Miao LY; The Affiliated Drum Tower Hospital of Nanjing University Medical College, Nanjing, 210008, China., Xie J; The Affiliated Cancer Hospital of Anhui University of Science and Technology, Huainan, 232033, China., Pan ZZ; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China., Duan YL; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China., Liu S; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China., Hou MJ; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China., Ding XS; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. 1020030749@cpu.edu.cn.
المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Jul; Vol. 149 (7), pp. 3895-3903. Date of Electronic Publication: 2022 Aug 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer-Verlag.
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/metabolism , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/metabolism, Humans ; Retrospective Studies ; Protein Kinase Inhibitors/adverse effects ; Mutation ; ErbB Receptors
مستخلص: Purpose: The aim of this retrospective study is to evaluate the impact on efficacy and safety between epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) alone and in combination with Shenqi Fuzheng injection (SFI) in patients with advanced NSCLC harboring epidermal growth factor receptor (EGFR) activating mutations.
Methods: Retrospectively, information of 88 patients receiving EGFR-TKIs as first-line targeted treatment or in combination with SFI in the Affiliated Drum Tower Hospital of Nanjing University Medical College and the Affiliated Cancer Hospital of Anhui University of Science and Technology was collected. The primary endpoint was to assess progression-free survival (PFS) and safety of EGFR-TKIs alone or in combination with SFI.
Results: Between January 2016 and December 2019, a total of 88 patients were enrolled in this research, including 50 cases in the EGFR-TKIs single agent therapy group and 38 cases in the SFI combined with EGFR-TKIs targeted-therapy group. The median PFS (mPFS) of monotherapy group was 10.50 months (95%CI 9.81-11.19), and 14.30 months (95%CI 10.22-18.38) in the combination therapy group. Compared to the single EGFR-TKIs administration, combinational regimen with SFI exhibited a lower incidence of rash and diarrhea in patients and was even better tolerated.
Conclusions: SFI combined with the first-generation EGFR-TKIs are more efficient, can prominently prolong the PFS and attenuate the adverse reactions in patients with advanced NSCLC with EGFR-sensitive mutations.
(© 2022. The Author(s).)
References: Medicine (Baltimore). 2019 Sep;98(39):e17350. (PMID: 31574877)
Biomed Pharmacother. 2019 Mar;111:1376-1382. (PMID: 30841452)
Phytother Res. 2014 Sep;28(9):1275-83. (PMID: 25087616)
J Cancer. 2020 Jan 1;11(2):334-344. (PMID: 31897229)
PLoS One. 2016 Mar 25;11(3):e0152270. (PMID: 27015629)
J Clin Oncol. 2008 May 20;26(15):2442-9. (PMID: 18458038)
J Cell Physiol. 2018 Sep;233(9):6722-6732. (PMID: 29215723)
Sci Transl Med. 2011 Mar 23;3(75):75ra26. (PMID: 21430269)
PLoS One. 2017 Sep 27;12(9):e0185254. (PMID: 28953950)
J Zhejiang Univ Sci B. 2017 Jan.;18(1):76-78. (PMID: 28070999)
J Environ Pathol Toxicol Oncol. 2017;36(2):151-158. (PMID: 29199595)
Ann Oncol. 2019 Jul 1;30(7):1127-1133. (PMID: 31070709)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Cancer Lett. 2020 Nov 28;493:167-177. (PMID: 32829007)
Med Sci Monit. 2019 Nov 09;25:8430-8437. (PMID: 31704907)
Cancer Discov. 2014 Sep;4(9):1046-61. (PMID: 24893891)
Thorac Cancer. 2019 Apr;10(4):898-903. (PMID: 30875149)
J Exp Clin Cancer Res. 2010 Oct 22;29:137. (PMID: 20969765)
J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266. (PMID: 33668021)
Integr Cancer Ther. 2019 Jan-Dec;18:1534735418816824. (PMID: 30511589)
Semin Cancer Biol. 2018 Oct;52(Pt 1):103-109. (PMID: 29183778)
Chin J Integr Med. 2019 Nov;25(11):812-819. (PMID: 31471834)
Nat Med. 2015 Jun;21(6):560-2. (PMID: 25939061)
Acta Pharm Sin B. 2021 Sep;11(9):2749-2767. (PMID: 34589395)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70. (PMID: 29168933)
J Ethnopharmacol. 2018 Jun 12;219:50-70. (PMID: 29501674)
Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287)
Integr Cancer Ther. 2022 Jan-Dec;21:15347354221083968. (PMID: 35313775)
World J Gastroenterol. 2004 Jul 1;10(13):1854-6. (PMID: 15222022)
Lancet Oncol. 2014 Feb;15(2):213-22. (PMID: 24439929)
Lancet Oncol. 2019 May;20(5):625-635. (PMID: 30975627)
Chin J Integr Med. 2022 Jan;28(1):81-87. (PMID: 32691286)
Biomed Pharmacother. 2021 May;137:111381. (PMID: 33601147)
J Tradit Chin Med. 2021 Aug;41(4):650-656. (PMID: 34392660)
Clin Cancer Res. 2006 Dec 15;12(24):7232-41. (PMID: 17189394)
J Thorac Oncol. 2016 Jan;11(1):39-51. (PMID: 26762738)
N Engl J Med. 2004 May 20;350(21):2129-39. (PMID: 15118073)
Rev Recent Clin Trials. 2019;14(2):120-128. (PMID: 30520383)
Front Immunol. 2021 Jan 21;11:609705. (PMID: 33552068)
Am J Chin Med. 2018;46(4):911-922. (PMID: 29754506)
Clin Lung Cancer. 2006 May;7 Suppl 4:S138-44. (PMID: 16764754)
Medicine (Baltimore). 2020 Aug 7;99(32):e20683. (PMID: 32769861)
Ann Oncol. 2017 Oct 01;28(10):2443-2450. (PMID: 28945850)
فهرسة مساهمة: Keywords: EGFR-TKIs; Non-small cell lung cancer; Progression free survival; Shenqi Fuzheng injection
المشرفين على المادة: 0 (shenqi fuzheng)
0 (Protein Kinase Inhibitors)
EC 2.7.10.1 (ErbB Receptors)
EC 2.7.10.1 (EGFR protein, human)
تواريخ الأحداث: Date Created: 20220825 Date Completed: 20230705 Latest Revision: 20230705
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10314878
DOI: 10.1007/s00432-022-04297-3
PMID: 36008690
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1335
DOI:10.1007/s00432-022-04297-3